These 3 Psychedelic Stocks Activated After Trump’s Executive Order

Trump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with high upside targets, these remain speculative investments with substantial risks.

04/27/2026, 2:38 PM • Investing

These 3 Psychedelic Stocks Activated After Trump’s Executive Order

Trump's April 2026 executive order supporting psychedelic drugs triggered FDA priority vouchers for select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—saw significant stock surges. While promising, these companies face challenges including mounting losses and high valuations, making them speculative investments.

04/27/2026, 12:22 PM • Investing

Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar

President Trump signed an executive order to fast-track FDA approval of psychedelic treatments for mental disorders, reducing review times from 6-10 months to 1-2 months. The order also allocates $50 million for private sector research. Three biotech companies with breakthrough therapy designations saw significant stock gains following the announcement.

04/20/2026, 11:07 AM • The Motley Fool

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.

02/27/2026, 11:44 AM • Benzinga

MindMed Reports Strong Q2 2025 Results

MindMed reported strong progress in phase 3 clinical trials for MM120 ODT, targeting generalized anxiety disorder and major depressive disorder. The company maintains a robust cash position of $237.9 million, sufficient to fund operations through 2027, and is preparing for potential market entry.

08/11/2025, 4:37 AM • The Motley Fool

1 Reason to Buy MindMed (MNMD)

MindMed, a clinical-stage biotech company developing brain health medications based on psychedelic compounds, faces regulatory challenges but shows potential as public support for medical psychedelic research grows.

08/07/2025, 5:25 AM • The Motley Fool